Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Dec 9, 2025
Date Accepted: Apr 27, 2026
Date Submitted to PubMed: May 25, 2026

The final, peer-reviewed published version of this preprint can be found here:

An Explainable AI Framework for Continuous Monitoring, Risk Stratification, and Clinical Decision Support in Primary Biliary Cholangitis: Protocol for a Multiphase Development and Validation Study

Njei B, Sidney Kanmounye U

An Explainable AI Framework for Continuous Monitoring, Risk Stratification, and Clinical Decision Support in Primary Biliary Cholangitis: Protocol for a Multiphase Development and Validation Study

JMIR Res Protoc 2026;15:e89279

DOI: 10.2196/89279

PMID: 42184424

A Multi-Phase Protocol for Developing and Validating an Explainable AI Framework for Continuous Monitoring, Risk Stratification, and Clinical Decision Support in Primary Biliary Cholangitis

  • Basile Njei; 
  • Ulrick Sidney Kanmounye

ABSTRACT

Background:

Primary biliary cholangitis (PBC) management remains limited by reliance on static biochemical markers, fragmented assessment of symptom burden, and inadequate noninvasive risk stratification for clinically significant portal hypertension (CSPH). Existing tools fail to integrate longitudinal laboratory trends, elastography, and patient-reported outcomes, and translation of risk assessment into guideline-concordant clinical action remains inconsistent.

Objective:

This study aims to develop, validate, and pilot an explainable artificial intelligence (AI) framework—AIm-PBC—for continuous disease monitoring, early prediction of CSPH complications, and delivery of guideline-based clinical decision support in patients with PBC.

Methods:

We will conduct a multi-phase study combining retrospective cohort analysis, prospective observational data collection, and implementation evaluation. At least 600 adults with confirmed PBC will be enrolled across academic hepatology centers. The AI framework will integrate longitudinal biochemical markers, noninvasive elastography metrics, and high-frequency patient-reported outcomes to generate an interpretable disease activity index and predict CSPH-related complications using gradient-boosted models with SHapley Additive Explanations. Outputs will be deployed via a SMART-on-FHIR–enabled electronic health record clinical decision support tool. Implementation will be evaluated using a randomized crossover simulation followed by a pragmatic pilot, assessing usability, cognitive load, provider adherence, and feasibility.

Results:

The primary outcomes include calibration and responsiveness of the disease activity index, discriminatory performance of the CSPH prediction model compared with established criteria, and effectiveness of the decision support tool, measured by improvements in guideline-concordant care, usability scores, and clinician cognitive workload. Secondary outcomes include fairness metrics and workflow efficiency.

Conclusions:

This protocol outlines a scalable, explainable AI framework designed to bridge gaps between disease monitoring, risk prediction, and clinical action in PBC. If successful, AIm-PBC may enhance early complication detection, improve symptom management, and support equitable, evidence-based care delivery in routine hepatology practice.


 Citation

Please cite as:

Njei B, Sidney Kanmounye U

An Explainable AI Framework for Continuous Monitoring, Risk Stratification, and Clinical Decision Support in Primary Biliary Cholangitis: Protocol for a Multiphase Development and Validation Study

JMIR Res Protoc 2026;15:e89279

DOI: 10.2196/89279

PMID: 42184424

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.